Preparation & Measurement Guide

Tirzepatide 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tirzepatide 10mg vial.

Research use only Educational comparator summary. This research material is not an approved drug product.
Vial Size Tirzepatide 10mg
Preparation 2mL bacteriostatic water
Concentration 5mg/mL after preparation
Documented Convention 2.5-15mg once weekly

1. Preparation and Measurement

Tirzepatide 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2.5mg once weekly 0.5mL / 50 units
Weeks 5-8 5mg once weekly 1mL / 100 units
Weeks 9-12 7.5mg once weekly 1.5mL / 150 units*
Weeks 13-16 10mg once weekly 2mL / 200 units*
Weeks 17-20 12.5mg once weekly 2.5mL / 250 units*
Weeks 21+ 15mg once weekly 3mL / 300 units*

Vial estimate: One 10mg vial contains approximately 4 administrations at the first listed amount; later rows exceed one vial's total content.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
  • Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Tirzepatide 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tirzepatide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents the approved weight-management escalation pattern as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated injector.

Primary Research and Regulatory References

  1. FDA Zepbound prescribing information
  2. SURMOUNT-1 tirzepatide obesity trial
  3. SURMOUNT-3 tirzepatide clinical trial

Research Materials

Review Tirzepatide 10mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: Tirzepatide 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.